Lexicon Pharmaceuticals
Market Cap
US$403.8m
Last Updated
2019/09/18 23:39 UTC
Data Sources
Company Financials +
Executive Summary
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products.
Snowflake
Fundamentals
High growth potential with imperfect balance sheet.
Risks
- Lexicon Pharmaceuticals has significant price volatility in the past 3 months.
Similar Companies
Share Price & News
How has Lexicon Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
72.7%
NasdaqGS:LXRX
-0.5%
US Biotechs
-0.02%
US Market
1 Year Return
-64.7%
NasdaqGS:LXRX
-11.3%
US Biotechs
1.6%
US Market
LXRX underperformed the Biotechs industry which returned -10.2% over the past year.
LXRX underperformed the Market in United States of America which returned 1.9% over the past year.
Share holder returns
| LXRX | Industry | Market | |
|---|---|---|---|
| 7 Day | 72.7% | -0.5% | -0.02% |
| 30 Day | 169.5% | -2.1% | 2.7% |
| 90 Day | -36.7% | -1.9% | 1.4% |
| 1 Year | -64.7%-64.7% | -10.6%-11.3% | 3.8%1.6% |
| 3 Year | -79.9%-79.9% | 4.6%1.1% | 45.2%35.8% |
| 5 Year | -63.3%-63.3% | 1.9%-3.0% | 61.8%44.1% |
Price Volatility Vs. Market
How volatile is Lexicon Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall St
Introducing Lexicon Pharmaceuticals (NASDAQ:LXRX), The Stock That Tanked 86%4 weeks ago | Simply Wall St
Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Path To ProfitabilityValuation
Is Lexicon Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?
In this section, we usually try to help investors determine whether Lexicon Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Lexicon Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
Next Steps
- Take a look at Lexicon Pharmaceuticals's' forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
Future Growth
How is Lexicon Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 5 analysts?
48.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Lexicon Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Lexicon Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
Lexicon Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Lexicon Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
Lexicon Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Lexicon Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Next Steps
Past Performance
How has Lexicon Pharmaceuticals performed over the past 5 years?
-8.6%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Lexicon Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare Lexicon Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Lexicon Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Lexicon Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
Return on Assets
It is difficult to establish if Lexicon Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Lexicon Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is Lexicon Pharmaceuticals's financial position?
Financial Position Analysis
Lexicon Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Lexicon Pharmaceuticals's long term commitments exceed its cash and other short term assets.
Debt to Equity History and Analysis
Lexicon Pharmaceuticals has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
Irrelevant to check if Lexicon Pharmaceuticals's debt level has increased considering it has negative shareholder equity.
Balance Sheet
Low level of unsold assets.
Lexicon Pharmaceuticals has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Lexicon Pharmaceuticals has less than a year of cash runway based on current free cash flow.
Lexicon Pharmaceuticals has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 32.6% each year.
Next Steps
Dividend
What is Lexicon Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Lexicon Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Lexicon Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Lexicon Pharmaceuticals has not reported any payouts.
Unable to verify if Lexicon Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Lexicon Pharmaceuticals has not reported any payouts.
Future Payout to Shareholders
No need to calculate the sustainability of Lexicon Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.
Next Steps
Management
What is the CEO of Lexicon Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?
7.3yrs
Average management tenure
CEO
Lonnel Coats (54yo)
5.2yrs
Tenure
US$3,123,433
Compensation
Mr. Lonnel Coats has been the Chief Executive Officer and President of Lexicon Pharmaceuticals, Inc., since July 7, 2014. Mr. Coats served as an Executive Vice President, President of Americas Region at Ei ...
CEO Compensation Analysis
Lonnel's remuneration is higher than average for companies of similar size in United States of America.
Lonnel's compensation has increased whilst company is loss making.
Management Age and Tenure
7.3yrs
Average Tenure
59yo
Average Age
The average tenure for the Lexicon Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Board Age and Tenure
12.1yrs
Average Tenure
64yo
Average Age
The average tenure for the Lexicon Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Insider Trading
More shares have been bought than sold by Lexicon Pharmaceuticals individual insiders in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 50,000 |
| Max Price | US$3.13 |
| Entity | Individual |
| Role | Chairman of the Board Chairman of the Board |
| Shares | 300,515 |
| Max Price | US$2.80 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 124,249 |
| Max Price | US$2.75 |
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 40,000 |
| Max Price | US$1.40 |
| Entity | Individual |
| Role | Chief Accounting Officer Vice President of Finance & Accounting |
| Shares | 10,000 |
| Max Price | US$1.14 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 24,000 |
| Max Price | US$1.18 |
Ownership Breakdown
Management Team
Jeffrey Wade (54yo)
Executive VP of Corporate & Administrative Affairs and CFO
- Tenure: 9.3yrs
- Compensation: US$1.41m
Robert Lefkowitz (75yo)
Consultant & Director
- Tenure: 18.6yrs
- Compensation: US$96.22k
Praveen Tyle (59yo)
Executive Vice President of Research & Development
- Tenure: 3.3yrs
- Compensation: US$1.46m
Lonnel Coats (54yo)
President
- Tenure: 5.2yrs
- Compensation: US$3.12m
James Tessmer (59yo)
Vice President of Finance & Accounting
- Tenure: 11.8yrs
- Compensation: US$508.34k
Pablo Lapuerta (56yo)
Executive VP & Chief Medical Officer
- Tenure: 4.6yrs
- Compensation: US$1.26m
Brian Crum
Vice President
- Tenure: 0yrs
Chas Schultz
Executive Director of Corporate Communications & Patient Advocacy
- Tenure: 18.7yrs
Alex Santini (60yo)
Executive VP & Chief Commercial Officer
- Tenure: 2.8yrs
- Compensation: US$1.23m
Kimberly Lee
Head of Investor Relations & Corporate Strategy
- Tenure: 0yrs
Board Members
Ray Debbane (64yo)
Chairman of the Board
- Tenure: 7.6yrs
- Compensation: US$80.39k
Sam Barker (76yo)
Independent Director
- Tenure: 19.5yrs
- Compensation: US$69.39k
Philippe Amouyal (60yo)
Independent Director
- Tenure: 12.1yrs
- Compensation: US$63.89k
Robert Lefkowitz (75yo)
Consultant & Director
- Tenure: 18.6yrs
- Compensation: US$96.22k
Christopher Sobecki (60yo)
Independent Director
- Tenure: 12.1yrs
- Compensation: US$60.39k
Judith Swain (70yo)
Independent Director
- Tenure: 12yrs
- Compensation: US$65.89k
Alan Nies (81yo)
Chairman of Medical Advisory Board & Independent Director
- Tenure: 16.5yrs
- Compensation: US$137.05k
Frank Palantoni (62yo)
Independent Director
- Tenure: 14.8yrs
- Compensation: US$69.39k
Lonnel Coats (54yo)
President
- Tenure: 5.2yrs
- Compensation: US$3.12m
Company Information
Lexicon Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Lexicon Pharmaceuticals, Inc.
- Ticker: LXRX
- Exchange: NasdaqGS
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$403.833m
- Shares outstanding: 106.27m
- Website: https://www.lexpharma.com
Number of Employees
Location
- Lexicon Pharmaceuticals, Inc.
- 8800 Technology Forest Place
- The Woodlands
- Texas
- 77381
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| LXRX | NasdaqGS (Nasdaq Global Select) | Yes | Common Shares | US | USD | Apr 2000 |
| LX31 | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Apr 2000 |
| LX31 | MUN (Boerse Muenchen) | Yes | Common Shares | DE | EUR | Apr 2000 |
Biography
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/18 23:39 |
| End of Day Share Price | 2019/09/18 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.